Tarone RE: Breast cancer trends among young women in the United States. Epidemiology. 2006, 17 (5): 588-590. 10.1097/01.ede.0000229195.98786.ee.
Article
PubMed
Google Scholar
Al-Kuraya K, Schramel P, Skeik , Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter G: Predominance of high grade pathway in breast cancer development of middle east. Modern Pathology. 2005, 18: 891-897. 10.1038/modpathol.3800408.
Article
PubMed
Google Scholar
Registry NC: Cancer Incidence Report Saudi Arabia 2002. Riyadh. 2007
Google Scholar
Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D: Breast cancer in the Eastern province of Saudi Arabia. Med Oncol. 1998, 15 (4): 241-247. 10.1007/BF02787207.
Article
CAS
PubMed
Google Scholar
Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK: Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncology. 1999, 16 (2): 95-103. 10.1007/BF02785842.
Article
CAS
Google Scholar
Pusztai L, Cristofanilli M, Paik S: New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol. 2007, 34 (2 Suppl 3): S10-6. 10.1053/j.seminoncol.2007.03.015.
Article
PubMed
Google Scholar
Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF: Molecular classification of breast cancer: limitations and potential. Oncologist. 2006, 11 (8): 868-877. 10.1634/theoncologist.11-8-868.
Article
CAS
PubMed
Google Scholar
Wood WCMH, Solin LJ, Olopade OI: Malignant tumors of the breast. 2005, Philadelphia: Lippincott Wiliams & Wilkins, 7
Google Scholar
Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR: Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19: 1865-1878.
PubMed
Google Scholar
Perou CM, Sorlie T, Eisen MB, Rijn van de M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.
Article
CAS
PubMed
Google Scholar
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003, 9: 2406-2415.
CAS
PubMed
Google Scholar
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor sub types in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn van de M, Perou CM: Immunohistochemical and clinicalcharacterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.
Article
CAS
PubMed
Google Scholar
Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005, 116: 340-350. 10.1002/ijc.21004.
Article
CAS
PubMed
Google Scholar
Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005, 65: 767-779.
CAS
PubMed
Google Scholar
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.
Article
CAS
PubMed
Google Scholar
Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Research. 2008, 10: R67-10.1186/bcr2128.
Article
PubMed
PubMed Central
Google Scholar
Al Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi MA: Distribution of molecular breast cancer subtypes in Middle Eastern-Saudi Arabian women - A pilot study. Ultrastructural Pathology. 2009, 33: 141-150.
Article
PubMed
Google Scholar
Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ: Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. Int J clin Exp Pathol. 2009, 444-455.
Google Scholar
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver van de M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007, 31 (1): 18-
Google Scholar
Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology. 2005, 18: 1027-1033. 10.1038/modpathol.3800438.
Article
CAS
PubMed
Google Scholar
Foulkes WD, Stefansson IM, Chappui PO, Bégi LR, Goffin JR, Won N, Trude M, Akslen LA: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. Journal of the National Cancer Institute. 2003, 95 (19): 1482-1485.
Article
CAS
PubMed
Google Scholar
De Manzoni G, Verlato G, Tomezzoli A: Study of Ki 67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol. 1998, 28: 534-537. 10.1093/jjco/28.9.534.
Article
CAS
PubMed
Google Scholar
Kleer CG, Giordano TJ, Braun T, Oberman HA: Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. Mod Pathol. 2000, 14 (3): 185-190. 10.1038/modpathol.3880282.
Article
Google Scholar
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst. 2009, 101: 736-750. 10.1093/jnci/djp082.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-overexpressing phenotypes. Hum Pathol. 2006, 37 (9): 1217-1226. 10.1016/j.humpath.2006.04.015.
Article
CAS
PubMed
Google Scholar
Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast cancer research and treatment. 2007, 110 (1): 183-188. 10.1007/s10549-007-9694-5.
Article
PubMed
Google Scholar
Brennan DJ, Gallagher WM: Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'. Breast Cancer Res. 2008, 10 (1): 102-10.1186/bcr1854.
Article
PubMed
PubMed Central
Google Scholar
Guedj M: A synthetic review of the five molecular Sorlie's subtypes in breast cancer. [http://mickael.guedj.googlepages.com/mguedjCITReview01.pdf]
Yu KD, Shen ZZ, Shao ZM: The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer. Breast Cancer Res Treat. 2009, 118 (3): 661-663. 10.1007/s10549-009-0522-y.
Article
CAS
PubMed
Google Scholar
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11 (16): 5678-5685. 10.1158/1078-0432.CCR-04-2421.
Article
CAS
PubMed
Google Scholar
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009, 27 (27): 4515-4521. 10.1200/JCO.2008.19.6873. Epub 2009 Aug 24
Article
CAS
PubMed
PubMed Central
Google Scholar
Rastelli F, Crispino S: Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008, 94 (3): 370-383.
PubMed
Google Scholar
Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006, 12 (15): 4614-4618. 10.1158/1078-0432.CCR-06-0248.
Article
CAS
PubMed
Google Scholar
Albain K, Barlow W, O'Malley F, Siziopikou k, Yeh IT, Ravdin P, Lew D, Farrar W, Burton G, Ketchel S, for the breast cancer intergroup of North America, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, estrogen (ER) and/or progesterone (PR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat. 2004, 88: S20-(abstract 37)
Google Scholar
Ma CX, Sanchez CG, Ellis MJ: Predicting endocrine therapy responsiveness in breast cancer. Oncology. 2009, 2: 133-142.
Google Scholar
Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006, 17 (5): 818-826. 10.1093/annonc/mdl016.
Article
CAS
PubMed
Google Scholar
Adelaide J: Integrated profiling of basal and luminal breast cancers. Cancer Research. 2007, 7: 231-
Google Scholar
Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M: Prognostic signifi cance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996, 2 (1): 147-154.
CAS
PubMed
Google Scholar
Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors -- a surrogate marker?. Cancer. 2003, 97 (5): 1321-1331. 10.1002/cncr.11188.
Article
CAS
PubMed
Google Scholar
de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007, 96 (10): 1504-1513. 10.1038/sj.bjc.6603756.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003, 63 (19): 6523-6531.
CAS
PubMed
Google Scholar
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G, IMPACT Trialists Group: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007, 99 (2): 167-170. 10.1093/jnci/djk020.
Article
CAS
PubMed
Google Scholar
Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol. 1995, 104 (1): 42-49.
Article
CAS
PubMed
Google Scholar
Bevilacqua P, Verderio P, Barbareschi M, Bonoldi E, Boracchi P, Dalla Palma P, Gasparini G: Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat. 1996, 37 (2): 123-133. 10.1007/BF01806494.
Article
CAS
PubMed
Google Scholar
Clahsen PC, Velde van de CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, Broek van den L, Vijver van de MJ: The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999, 25 (4): 356-363. 10.1053/ejso.1999.0657.
Article
CAS
PubMed
Google Scholar
Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population based study. Clin Cancer Res. 2003, 9 (3): 923-930.
CAS
PubMed
Google Scholar
Goodson WH, Moore DH, Ljung BM, Chew K, Mayall B, Smith HS, Waldman FM: The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat. 2000, 59 (2): 113-123. 10.1023/A:1006344010050.
Article
CAS
PubMed
Google Scholar
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, International Breast Cancer Study Group: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node negative breast cancer. J Natl Cancer Inst. 2008, 100 (3): 207-212. 10.1093/jnci/djm289.
Article
CAS
PubMed
Google Scholar
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL: The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. Journal of Clinical Oncology. 2004, 22 (1): 86-96. 10.1200/JCO.2004.09.128.
Article
CAS
PubMed
Google Scholar
Barbiti A, Cosmi EV, Sidoni A, Collin P, Parpora MG, Ferri I, Luthy M, Lauro V, Bucciarelli E: Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Res. 1997, 17 (1A): 401-405.
Google Scholar
Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB: Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2005, 18 (3): 374-381. 10.1038/modpathol.3800254.
Article
CAS
PubMed
Google Scholar
Kuroda H, Ishida F, Nakai M, Ohnisi K, Itoyama S: Basal cytokeratin expression in relation to biological factors in breast cancer. Hum Pathol. 2008, 39 (12): 1744-1750. 10.1016/j.humpath.2008.06.007.
Article
CAS
PubMed
Google Scholar
Siziopikou KP, Cobleigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007, 16 (1): 104-107. 10.1016/j.breast.2006.09.003.
Article
PubMed
Google Scholar
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008, 26 (26): 4282-4288. 10.1200/JCO.2008.16.6231.
Article
PubMed
Google Scholar
Chen JQ, Russo J: ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009, 1796 (2): 162-175.
CAS
PubMed
PubMed Central
Google Scholar
Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H: Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008, 61: 553-60. 10.1136/jcp.2008.055475.
Article
CAS
PubMed
Google Scholar